Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein, a First-in-Class adjunct in the real-time intraoperative visualization of nerves during head and neck surgical procedures in adults

September 25, 2026 SDBN News, Syndication Comments Off on Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein, a First-in-Class adjunct in the real-time intraoperative visualization of nerves during head and neck surgical procedures in adults

SAN DIEGO–(BUSINESS WIRE)–Alume Biosciences Announces U.S. FDA Breakthrough Therapy Designation Granted for Bevonescein
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks